lion from Merck to fund Saturnus' research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck has exclusive rights to acquire Saturnus for a pre-determined option payment in addition to success-based earnouts.

The strategic partnership will focus on next-generation precision cardiology that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Genetic cardiomyopathies represent a vital entry point for Merck’s cardiovascular business, addressing a significant unmet need in a market characterized by no approved therapies for genetic drivers.

Merck is committed to leveraging advanced technologies and data science to accelerate the discovery and delivery of breakthrough medicines. This partnership reinforces its broader strategy to enhance rese
=*=*=*=*=*=
当前为第3/5页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页